Equfina tablets 50 mg for Parkinson’s disease (safinamide mesylate, Xadago)
What are Equfina tablets 50 mg for Parkinson’s disease (safinamide mesylate, Xadago)?
The active principle of Equfina tablets is safinamide mesylate, a selective monoamine oxidase B inhibitor. It suppresses dopamine degration in the brain an increases the level of available dopamine. As the result, Equfina tablets improve wearing-off phenomenon in patients with Parkinson's disease undergoing treatment with levodopa.
Active principles: safinamide mesylate
Amount: 100 tablets
Maker: Eisai Co., Ltd., Tokyo, Japan
Indications: improving wearing-off phenomenon in patients with Parkinson's disease
How to take
Equfina tablets should be used concomitantly with levodopa-containing preparations. Adults should take 1 tablet (50 mg as safinamide) at a time, once a day. Your doctor may increase the dosage up to 100 mg at a time, once a day, according to the symptoms.
Contraindications: do not use for pregnant, possibly pregnant or breastfeeding women. Do not use for patients with retina-related diseases, a history of those or liver dysfunction.
- These tablets may cause strong drowsiness. Patient should not drive a car, work at heights or operate dangerous mechanisms while taking them.
- If patient notices any symptoms of orthostatic hypotension or hypotension, consult with doctor in charge.
- If a patient or their family notice unusual behavioral symptoms like gambling, excessive shopping or drastically increased sexual desire, consult with doctor in charge.
- If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.